Below is a list of our ongoing clinical trials, sponsoring agencies, and associated clinical conditions.
Diabetic Macular Edema
Diabetic Retinopathy Clinical Research Network
Treatment for Central-Involved Diabetic Macular Edema in Eyes with Very Good Visual Acuity (Protocol V).
Astellas Pharma Europe
A Phase 2, Double-Masked, Randomized, Active Controlled Study to Evaluate the Efficacy and Safety of ASP8232 in Reducing Central Retinal Thickness in Subjects with Diabetic Macular Edema (VIDI).
Aerpio Therapuetics
A Phase 2, Randomized, Active-Controlled, Double-Masked, Multicenter Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects with Diabetic Macular Edema.
Vitreo-Macular Traction
Thrombogenics
Ocriplasmin (Jetrea) Research to Better Inform Treatment (ORBIT).
Nova Southeastern University
Phase 1 Study of Optical Coherence Tomography Images to Identify the Prevalence of Vitreomacular Adhesion and Associated Maculopathies (VAST).
Age-Related Macular Degeneration
Alcon/Novartis
A Two-Year, Randomized, Double-Masked, Multicenter, Three-Arm Study Comparing the Efficacy and Safety of RTH258 versus Aflibercept in Subjects with Neovascular Age-Related Macular Degeneration (HAWK).
Allergan
Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients with Neovascular Age-Related Macular Degeneration (SEQUOIA).
Regeneron Pharmaceuticals
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients with Neovascular Age-Related Macular Degeneration (ONYX).
OHR Pharmaceutical
A Phase 3 Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution, 0.2% Twice Daily in Subjects with Neovascular Age-Related Macular Degeneration (MAKO).
Non-Proliferative Diabetic Retinopathy
Thrombogenics
A Phase 2, Randomized, Double Masked, Sham Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Ocriplasmin In Inducting Total Posterior Vitreous Detachment in Subjects with Non-Proliferative Diabetic Retinopathy (CIRCLE).